<DOC>
	<DOCNO>NCT02773225</DOCNO>
	<brief_summary>The aim study improve treatment Moderate Aplastic Anemia ( MAA ) evaluate safety efficiency Eltrombopag new treatment option patient therapy require MAA .</brief_summary>
	<brief_title>Efficacy Safety Eltrombopag + CSA Patients With Moderate Aplastic Anemia ( EMAA )</brief_title>
	<detailed_description>After enrollment ( see detail inclusion exclusion criterion ) patient randomize either Placebo Eltrombopag arm . The randomization double blind . Randomization take account patient 's age disease severity stratify 4 block combination ensure homogeneity treatment arm . All patient receive background therapy CSA , regardless randomisation group , treat MAA accord current standard care . Eltrombopag ( Placebo ) give daily start dose 150 mg orally 75 mg tablet daily ( 2 tablet Eltrombopag placebo per day ) , ( Olnes et al NEJM 2012 ) . In Asian patient Eltrombopag ( Placebo ) give daily start dose 75 mg orally ( 1 tablet Eltrombopag placebo per day ) . In Asian-Caucasian patient dose reduction start dose carry , cautious observation liver function due possibility alter Eltrombopag metabolism recommend . Dose reduction : In patient without history thromboembolism know risk factor thrombembolism dose reduction ( possibility alternate dose schedule give ) recommend platelet count increase &gt; 150 G/L . - Dosage decrease achieve platelet count 100 150 G/L reach sufficient erythrocyte granulocyte response ( see 10.1 ) . - If platelet count decrease 100 G/L Eltrombopag dose escalate . - Eltrombopag discontinue platelet count exceed 450 G/L could restart low dose decrease platelet count 150 G/L . In patient history thromboembolism know risk factor thromboembolism ( e. g. Factor V Leiden , ATIII deficiency , antiphospholipid syndrome , PNH GPI-deficient granulocyte population &gt; 50 % , prolong period immobilization , contraceptives hormone replacement therapy surgery ) dose reduction recommend platelet count increase &gt; 100 G/L - The target platelet count 70-120 G/L reach sufficient erythrocyte granulocyte response ( see 10.1 ) . - If platelet count decrease 70 G/L Eltrombopag dose escalate . - Eltrombopag discontinue patient history risk factor thromboembolism platelet count exceed 150 G/L . Duration follow : Last Follow 24 month end study treatment . Patients receive Eltrombopag placebo within study minimum 6 month . Exceptions patient disease progression Severe Very Severe AA patient inacceptable adverse event within first 6 month . Eltrombopag administer maximum period 12 month within protocol . Recent data show response hematopoiesis refractory severe aplastic anemia sustain discontinuation Eltrombopag25 . As long-term effect investigational treatment objective study , follow-up patient cover 24 month end study treatment accord protocol</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . Current diagnosis Moderate Aplastic Anemia require standard treatment CSA without prior specific therapy . MAA define Aplastic Anemia fulfil follow criterion : evidence disease cause marrow failure hypocellular bone marrow age depression least two three peripheral blood count normal value : absolute neutrophil count ( ANC ) &lt; 1.2 G/L &gt; 0.5 G/l platelet count &lt; 70 G/L absolute reticulocyte count &lt; 60 G/L without fulfil criterion SAA ( hypocellularity bone marrow 25 % depression two three peripheral count : ANC &lt; 0.5 G/L , platelet count &lt; 20 G/L , reticulocyte count &lt; 20 G/L ) 2 . In study need treatment CSA define : 2a ) transfusionindependent MAA : ANC &lt; 1.0 G/L hemoglobin &lt; 8.5 g/dl reticulocyte count &lt; 60 G/L platelet count &lt; 30 G/L significant clinical symptom ( infection , bleeding , anemia ) 2b ) transfusiondependent moderate aplastic anemia Platelet transfusion dependency define prophylactic transfusion ( platelet count &lt; 10 G/L bleeding ) therapeutic transfusion 12 week prior study entry Red cell transfusion dependency define transfusion least 4 unit pack red blood cell concentrate ( PRBC ) 12 week prior study entry 3 ) A sign date informed consent necessary conduct studyspecific procedure . 1 . Age &lt; 18 year 2 . Severe Very Severe Aplastic Anemia ( hypocellularity bone marrow 25 % depression two three peripheral count : ANC &lt; 0.5 G/L , platelet count &lt; 20 G/L , reticulocyte count &lt; 20 G/L ) 3 . Constitutional aplastic anemia ( Fanconi anemia Dyskeratosis congenita ) 4 . Clonal myeloid disorder base cytogenetic finding perform within 12 week study entry . Especially , patient cytogenetic abnormality recurrent MDS eligible study . 5 . Bone marrow reticulin fibrosis grade 3 great 6 . Severe concurrent disease preclude patient 's ability tolerate protocol therapy 7 . ALT &gt; 3 time upper limit normal elevation progressive , persistent 4 week , accompany increase direct bilirubin , accompany clinical symptom liver injury evidence hepatic decompensation 8 . Infection adequately respond appropriate therapy 9 . HIVpositivity ( patient Hepatitis B Hepatits Cpositivity combination hepatic failure ( see criterion 7 ) exclude ) 10 . Moribund status likely death within 3 month 11 . History malignancy localize tumor diagnose one year previously treat surgically curative intent ( instance squamous cell skin cancer , stage 1 , breast cancer situ , cervical carcinoma situ ... ) . 12 . Prior specific treatment Aplastic Anemia immunosuppression androgens interleukin2receptorantibodies . The use drug context disorder diagnosis aplastic anemia exclusion criterion treatment finish longer 6 month study entry . 13 . Treatment hematological effective drug ( include erythropoetin ) within 3 month study entry well treatment corticosteroid GCSF within 3 week enrollment 14 . Known hypersensitivity Eltrombopag components 15 . Known hypersensitivity Ciclosporin 16 . Current nursing , pregnancy , unwillingness take oral contraceptive use barrier method birth control refrain pregnancy well miss positive pregnancy test within last 14 day inclusion woman childbearing potential course study . 17 . Inability understand investigational nature study give inform consent . 18 . Renal failure creatinine &gt; 2Ã— upper limit normal . 19 . Uncontrolled hypertension 20 . Participation study use investigational drug treatment investigational drug within 30 day precede first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>non severe Aplastic Anemia ,</keyword>
</DOC>